Risk Factors for Death from Influenza A (H1N1)pdm09, State of São Paulo, Brazil, 2009

Ana Freitas Ribeiro1,2,*, Alessandra Cristina Guedes Pellini1, Beatriz Yuko Kitagawa1, Daniel Marques1, Geraldine Madalosso1, Gerrita de Cassia Nogueira Figueira1, João Fred1, Ricardo Kerti Mangabeira Albernaz1, Telma Regina Marques Pinto Carvalhanas1, Dirce Maria Trevisan Zanetta2

1 Epidemiological Surveillance Center, Disease Control Coordination, State of São Paulo Department of Health, São Paulo, Brazil, 2 Department of Epidemiology, School of Public Health, University of São Paulo, São Paulo, Brazil

* Current address: Institute of Infectious Diseases Emílio Ribas, São Paulo, SP, Brazil.
** Current address: Intermedici Piracicaba, São Paulo, Brazil.

Abstract

This case-control study aimed to assess the risk factors for death from influenza A(H1N1)pdm09 in patients with laboratory confirmation, who had severe acute respiratory illness-SARI and were hospitalized between June 28th and August 29th 2009, in the metropolitan regions of São Paulo and Campinas, Brazil. Medical charts of all the 193 patients who died (cases) and the 386 randomly selected patients who recovered (controls) were investigated in 177 hospitals. Household interviews were conducted with those who had survived and the closest relative of those who had died. 73.6% of cases and 38.1% of controls were at risk of developing influenza-related complications. The 18-to-59-year age group (OR = 2.31, 95%CI: 1.31–4.10 (reference up to 18 years of age)), presence of risk conditions for severity of influenza (OR = 1.99, 95%CI: 1.11–3.57, if one or OR = 6.05, 95%CI: 2.76–13.28, if more than one), obesity (OR = 2.73, 95%CI: 1.28–5.83), immunosuppression (OR = 3.43, 95%CI: 1.28–9.19), and search for previous care associated with the hospitalization (OR = 3.35, 95%CI: 1.75–6.40) were risk factors for death. Antiviral treatment performed within 72 hours of the onset of symptoms (OR = 0.17, 95%CI: 0.08–0.37, if within 48hours, and OR = 0.30, 95%CI: 0.11–0.81, if between 48 and 72 hours) was protective against death. The identification of high-risk patients and early treatment are important factors for reducing morbimortality from influenza.

Introduction

In March and April 2009, health professionals warned the Mexican Ministry of Health about the increase in incidence of acute respiratory illness in young adults [1]. In April, a new viral subtype of influenza A(H1N1)pdm09, a combination of swine, avian and human virus, was identified in the United States and in samples originated from Mexico [2,3]. On April 25th, the
World Health Organization-WHO declared that this event was a public health emergency and, on June 11th, it announced the influenza pandemic [4,5].

In Brazil, a new subtype of human influenza is included in the list of compulsory notification diseases since 2006, which is done in the Information System for Notifiable Diseases-SINAN. In May 2009, the first cases of Influenza-A (H1N1)pdm09 were confirmed in the country. With the beginning of the epidemics, the Secretariat of Health Surveillance elaborated a system of online reporting through the web application SINAN-flu to make the registration of cases easier and more opportune. After confirmation of transmission in the country in July, the guidelines for influenza surveillance gave priority for notification and investigation of cases of influenza-associated severe acute respiratory syndrome. During that year, 48,978 cases were confirmed and 2,051 deaths occurred, mainly in Southern and Southeastern regions, with mortality rates of 3.0 and 1.2 deaths per 100,000 inhabitants, respectively [6]. In São Paulo state, 12,002 cases were confirmed, of which 578 resulted in deaths, with a mortality rate of 1.4 per 100,000 inhabitants [7]. The epidemic initially spread through the metropolitan regions of São Paulo and Campinas, subsequently reaching the inner cities of the state, with a peak of transmission in the first week of August [8].

In the United States, between April and May 2009, 60% of cases occurred in children and adolescents, and only 5% in those aged 51 years and over [9]. In Mexico, 87% of deaths and 71% of cases were concentrated in those between five and 59 years, whereas the seasonal influenza from 2005 to 2008 totaled 17% and 32%, respectively [10]. In 2009, hospitalization rate varied from 2.9 per 100,000 inhabitants in Japan to 24.5 in Argentina, while this rate was 8.8 in Brazil. The presence of co-morbidity was frequent among hospitalized cases, from 27% in the United States to 79% in Brazil [11]. Chronic pulmonary diseases were the main pre-existing diseases among children and adults hospitalized in the United States [12].

Being aged 18 or over, antiviral therapy beginning more than 48 hours after the onset of symptoms [13] and the presence of obesity (BMI >40) or chronic liver disease [14] were risk factors for greater severity in patients hospitalized due to influenza A(H1N1)pdm09, admitted to Intensive Care Units-ICU. A study performed with patients admitted to ICUs in Spain showed that cancer, immunodeficiency and morbid obesity were associated with death from influenza in adults [15]. Although several studies have sought to identify factors associated with disease severity, few have analyzed the risk factors for death.

The present study aimed to identify risk factors for death from influenza A(H1N1)pdm09 in hospitalized patients with associated severe acute respiratory illness-SARI. This knowledge is important to support future interventions during pandemics, taking into account the organization of health services and selection of priority groups for vaccination.

Methods

The state of São Paulo is the most populous in Brazil, with an estimated population of 41,384,089 inhabitants in 2009 (21.6% of the Brazilian population). The metropolitan region of São Paulo includes 39 cities, and that of Campinas, 42 cities, corresponding to 47.8% and 9.6% of the state’s population, respectively.

During the epidemic in 2009, 7,400 patients who lived in the metropolitan regions of São Paulo and Campinas were notified and confirmed as having influenza A(H1N1)pdm2009, of whom 4,066 were associated with SARI, resulting in 328 deaths.

A case-control study was performed with patients who had been hospitalized for more than 24 hours, with a confirmed infection of Influenza A(H1N1)pdm09 and SARI, between June 28th and August 29th 2009. The study period included the majority of disease confirmations and deaths from this epidemic in 2009, as shown in Fig. 1.
The patients were identified in the SINAN database, using the following variables for selecting the cases and controls: RT PCR (positive for influenza A(H1N1)pdm2009), final classification (confirmed), criteria (laboratory), evolution (recovered or death), hospitalization (yes), date of hospitalization (28/06/2009 to 29/08/2009), municipalities of residence and hospitals (metropolitan areas of São Paulo and Campinas).

At the time the patients were selected for the study, the SINAN included 193 reported and confirmed deaths of patients with influenza A(H1N1)pdm2009 and SARI, all of which were assessed in this study (cases). For each case of death, two control patients were selected among the 1988 patients hospitalized during the study period with reported and confirmed influenza A(H1N1)pdm2009 and SARI who recovered. The controls were time-paired randomly selected from those hospitalized in the same epidemiological week (EW) or, if necessary, one week later than the date of hospitalization of cases to prevent possible differences in opportunity of treatment and clinical management protocol.

Data of the study were collected by trained health professionals using two standardized questionnaires. The hospital questionnaire collected information from medical charts, evaluated in 177 hospitals were patients were hospitalized. Of these, 56.5% belonged to the Unified Health System-SUS and 43.5% were private hospitals. The following data were collected: previous pathological history, occurrence of pregnancy, health care, symptomatology during admission, laboratory and radiological tests, need for ICU admission, treatment, complications and disease progression. The International Classification of Diseases, 10th revision-ICD-10, was used for coding comorbidities indicated in the medical charts. The Ministry of Health provided the antiviral drug known as Oseltamivir for treatment during the pandemic. The protocol for clinical management established that the treatment was for cases hospitalized with SARI and ambulatory patients with risk conditions for severity. Treatment should be started within 48 hours after symptom onset.

Fig 1. Number of confirmed cases and deaths from Influenza A(H1N1)pdm 09 among hospitalized SARI patients, according to the epidemiological week of onset of symptoms, metropolitan regions of São Paulo and Campinas, Brazil 2009.

doi:10.1371/journal.pone.0118772.g001
All patients studied had laboratory confirmations of influenza A(H1N1)pdm09 from respiratory secretion samples analyzed using the RT-PCR method, performed by the Adolfo Lutz Institute [16]. The definition of SARI included: fever associated with cough and dyspnea; pneumonia; respiratory insufficiency; tachypnea; radiological changes compatible with pneumonia; oxygen therapy or mechanical ventilation. SARI was confirmed in all cases and controls selected for the study by data their on medical charts.

Household interviews were conducted in 161 cases (83.4%), with 14 refusals (7.3%) and 18 (9.3%) addresses not found. A total of 337 (85.1%) controls were interviewed, with 6 (1.5%) refusals and 43 (11.1%) addresses not found. The household questionnaire included socio-demographic data, history of previous care related to the episode that led to hospitalization and presence of influenza vaccination. Occupations were grouped according to the occupational pyramid of influenza risk [17]. For cases, interviews were conducted with the closest family members; for controls, with the patients themselves, excluding children, whose parents/legal guardians responded for them.

After data collection, questionnaires were assessed by supervisors to verify the consistency of information and the fulfillment of criteria to include patients in this study. Hospital and household questionnaires were input to the Sphynx database, version 5.

The present study began in order to assist with decisions on surveillance and control actions. The use of data was approved by the Research Ethics Committee, School of Public Health, University of São Paulo-FSP-USP (protocol 2283, OF.COEP/312/11). Data collection was performed in accordance with the recommendations of the National Health Council for Human Research, including the signing of an informed consent form by patients, family members or legal guardians.

Clinical and demographic characteristics are shown as median and inter-quartile intervals or percentages, and comparisons were made using the Mann-Whitney U or chi-square tests, as required. Odds ratio-OR and 95% confidence intervals-95%CI were calculated to assess the factors associated with death. Variables with p-value < 0.20 in the univariate analysis and adjustment variables were selected for the multiple logistic regression, which used forward stepwise strategy. The model including all patients assessed the following dichotomous categorical variables: health insurance, previous care, vaccination against influenza in 2009, sex (reference category = male); and the following risk conditions: diabetes mellitus, obesity, chronic kidney disease, chronic liver disease, immunosuppression, chronic cardiovascular disease, chronic neurological disease and delay in development, using the absence of a condition as a reference category. The model also assessed: age group [<18 years (reference), 18 to 59 years, ≥ 60 years], use of antiviral therapy [no use (reference category), ≤ 48 hours after the onset of symptoms, > 48 and ≤ 72 hours, > 72 hours], high-risk individuals or those with any of the risk conditions listed above adapted from the Centers for Disease Control and Prevention-CDC [18] [no condition (reference category), one condition, and two or more conditions], and time between onset of symptoms and admission in days as the continuous variable. The model was controlled for epidemiologic week of admission at hospital (categorized as EW26-28 (reference), EW29-31 and EW31-34), and income. A second model was developed with patients aged 18 years and over, which also assessed level of education [without formal education or incomplete primary education, complete primary education, complete secondary education, complete higher education (reference category)] and occupational risk [very high and high, average and low (reference category)]. Patients aged 18 to 22 years with incomplete higher education were included in reference category of education. For the modelling, patients with no occupation were included in the reference category of occupational risk. Significance of variables was assessed by Wald test and adjustment of models by Hosmer-Lemeshow test.
The analyses were performed using SPSS software, version 17.0. P-values < 0.05 were considered to be significant.

**Results**

Table 1 presents the socioeconomic characteristics of patients and information associated with the disease obtained from the household interviews. Among patients aged 18 years and over, there was a higher risk of death for those without formal education or with incomplete primary education, OR 2.33 (95% CI 1.13–4.89) and complete primary education, OR 3.06 (95% CI 1.41–6.82), when compared to those with higher education. Distribution of ethnic groups, family income and history of smoking were not associated with death. The history of previous vaccination against seasonal influenza in 2009 showed protection against death. Health

| CHARACTERISTICS                                      | N (%) CASE<sup>a</sup> (n = 159) | N (%) CONTROL<sup>a</sup> (n = 335) | OR<sup>b</sup> (95% CI) |
|------------------------------------------------------|----------------------------------|-----------------------------------|-------------------------|
| Ethnicity<sup>c</sup>                                 |                                  |                                   |                         |
| White                                                | 113 (71.1)                       | 219 (65.4)                        | 1                       |
| Black/Mixed                                          | 43 (27.0)                        | 106 (31.6)                       | 0.79 (0.51–1.20)        |
| Private health insurance                             | 67 (42.1)                        | 166 (49.6)                       | 0.74 (0.51–1.08)        |
| Previous care                                        | 138 (86.8)                       | 214 (63.9)                       | 3.71 (2.25–6.30)        |
| 2009 influenza vaccine<sup>d</sup>                   | 13 (8.2)                         | 53 (15.8)                        | 0.51 (0.26–0.95)        |
| Household income<sup>e</sup>                         |                                  |                                   |                         |
| Up to 02 MW                                          | 60 (37.7)                        | 138 (41.2)                       | 1.13 (0.58–2.26)        |
| 02 to 04 MW                                          | 54 (34.0)                        | 87 (26.0)                        | 1.61 (0.82–3.27)        |
| 04 to 08 MW                                          | 27 (17.0)                        | 61 (18.2)                        | 1.15 (0.54–2.48)        |
| > 08 MW                                              | 15 (9.4)                         | 39 (11.6)                        | 1                       |

**CHARACTERISTICS OF PATIENTS**

| CHARACTERISTICS                                      | N (%) CASE<sup>a</sup> (n = 131) | N (%) CONTROL<sup>a</sup> (n = 192) | OR<sup>b</sup> (95% CI) |
|------------------------------------------------------|----------------------------------|-----------------------------------|-------------------------|
| Level of education<sup>f</sup>                       |                                  |                                   |                         |
| Without formal education/Incomplete primary education | 35 (26.7)                        | 43 (22.3)                        | 2.33 (1.13–4.89)        |
| Complete primary education                           | 28 (21.4)                        | 26 (13.5)                        | 3.06 (1.41–6.82)        |
| Complete secondary education                         | 52 (39.7)                        | 77 (40.1)                        | 1.90 (0.98–3.79)        |
| Complete higher education                            | 16 (12.2)                        | 46 (24.0)                        | 1                       |
| Smoking<sup>g</sup>                                  | 23 (17.6)                        | 41 (21.4)                        | 0.78 (0.44–1.38)        |
| Occupation                                           | 85 (64.9)                        | 138 (71.9)                       | 0.72 (0.45–1.17)        |
| Occupational risk                                    |                                  |                                   |                         |
| Very high and high<sup>i</sup>                       | 2 (2.4)                          | 21 (15.6)                        | 0.15 (0.02–0.61)        |
| Average<sup>i</sup>                                  | 52 (61.2)                        | 65 (48.2)                        | 1.26 (0.70–2.27)        |
| Low<sup>i</sup>                                      | 31 (36.5)                        | 49 (36.3)                        | 1                       |

<sup>a</sup>Data collected from household interviews  
<sup>b</sup>Unadjusted OR  
<sup>c</sup>2 controls ignored; 3 (1.9%) cases and 8 (2.4%) controls were Asian/Indigenous  
<sup>d</sup>12 cases and 3 controls ignored  
<sup>e</sup>3 cases and 10 controls ignored, MW minimum wage (R$ 465.00 or US$ 236.34 at the time of this study)  
<sup>f</sup>1 cases ignored; complete higher education includes 16 patients aged 18 to 22 years with incomplete higher education (2 cases and 14 controls)  
<sup>g</sup>Smoked at the time of hospitalization  
<sup>i</sup>Physicians, nurses, dentists, other health professionals and supporting professionals in health services  
<sup>j</sup>Education, business, service and administrative professionals with close contact with the population  
<sup>k</sup>Management professionals and other university and technical professionals without close contact with the population.

doi:10.1371/journal.pone.0118772.t001
professionals, considered to be at a high risk of developing influenza, showed protection against death, OR 0.15 (95% CI 0.02–0.61). Patients who had sought care prior to hospitalization had a risk of death 3.70 times (95% CI 2.25–6.30) that of patients without previous care, with a predominance of emergency care (45.34%).

Table 2 presents the distribution of cases and controls according to variables assessed in the hospital investigation. Median age of cases was higher than that of controls (p < 0.001) and the 18-to-59-year age group had an OR for death of 4.03 (95% CI 2.62–6.31), compared to those aged less than 18 years. Elderly individuals were also at a significant risk of death.

There were no differences in sex distribution in either group. With regard to risk conditions for severity, 73.6% of cases and 38.1% of controls reported having at least one risk factor, with an OR of 4.49 (95% CI 3.09–6.60). When individuals with more than one of these conditions were assessed, the risk of death increased, OR 10.29 (95% CI 6.04–17.85). The following medical conditions were risk factors for death: obesity, diabetes mellitus, chronic cardiovascular diseases, chronic kidney diseases, neurological diseases and delay in development, chronic liver diseases and immunosuppressive diseases. The immunosuppression-related diseases were: neoplasms (n = 18), HIV/AIDS (n = 8), organ transplants (n = 6), autoimmune diseases (n = 5) and use of immunosuppressants (n = 3).

Of the 212 women of reproductive age (10 to 49 years) who were studied, 33.5% were pregnant and there were no differences in the frequency of pregnancy in either group.

The use of antiviral treatment during hospitalization was a protective factor against death, with an OR of 0.67 (95% CI 0.45–0.98). When time between onset of symptoms and beginning of antiviral treatment was assessed, there was an 81% protection among individuals who received treatment within the first 48 hours, with an OR of 0.19 (95% CI 0.11–0.35), and 65% between 48 and 72 hours, with an OR of 0.35 (95% CI 0.16–0.74). After 72 hours, there was no significant protection. Median of days between date of onset of symptoms and date of hospitalization was 5.0 among cases and 2.0 among controls (p < 0.001). Among patients with chronic pulmonary disease, median was 4.0 days among cases and 2.0 days among controls; among those with asthma, 4.5 days and 2.0 days; and among pregnant women, 4.0 days and 2.0 days, respectively. With regard to health professionals, the median between the date of onset of symptoms and that of hospitalization was three days for both cases and controls. Median between date of hospitalization and of death or hospital discharge was seven days among cases and four days among controls (Table 2).

According to medical charts, fever and cough occurred in 87.8% of cases and 79.3% of controls; and the proportions of dyspnea were 87% and 62.7%, respectively. The definition of cases of Severe Acute Respiratory Syndrome – SARS (fever + cough + dyspnea) based on information obtained from medical charts occurred in 68.9% of cases and 56.5% of controls. Vomiting and diarrheea were present in 8% of cases and 18% of controls. Treatment with antibiotics was used in 95.8% of cases and 73.1% of controls. The mean number of antibiotics used was 4.0 and 1.8 respectively. Among cases, there was a higher proportion of hospitalizations in intensive care units (83.4% vs 16.8%), use of mechanical ventilation (94.8% vs 10.8%) and dialysis (25.0% vs 2.3%). The proportion of complications was higher among cases than controls, with an emphasis on: respiratory distress syndrome (64.7% vs 4.9%), shock (69.4% vs 1.0%), sepsis (63.2% vs 2.3%) and kidney complications (44.6% vs 1.3%), respectively.

Table 3 shows the laboratory findings of entry tests of patients in the hospital. Cases had lower numbers of leukocytes and platelets and higher values of creatine phosphokinase-CPK, lactic dehydrogenase-LDH, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, urea and creatinine than controls, with statistical significance.

In sub-group analysis, previous conditions of risk for severity and obesity were risk factors for death in univariate analysis for children younger than 18 years and women of reproductive age.
Table 2. Demographic and clinical variables of patients hospitalized due to influenza A(H1N1)pdm09 associated with Severe Acute Respiratory Illness, who died (case) or recovered (control), metropolitan regions of São Paulo and Campinas, state of São Paulo, Brazil, 2009.

| CHARACTERISTICS                                      | N (%) CASE\(^a\) (n = 193) | N (%) CONTROL\(^a\) (n = 386) | OR\(^b\) (95% CI) |
|------------------------------------------------------|------------------------------|--------------------------------|-------------------|
| Age group (years)                                     |                              |                                |                   |
| < 18                                                  | 31 (16.1)                    | 168 (43.5)                     | 1                 |
| 18–59                                                 | 152 (78.8)                   | 204 (52.8)                     | 4.03 (2.62–6.31)  |
| 60 and more                                           | 10 (5.2)                     | 14 (3.6)                       | 3.84 (1.52–9.50)  |
| Age, median (IQR)\(^c\)                              |                              |                                |                   |
| 32.97 (22.89–46.32)                                  | 20.88 (4.99–34.32)           | p < 0.001                      |
| Sex, female                                           |                              |                                |                   |
| None                                                  | 51 (26.4)                    | 239 (61.9)                     | 1                 |
| At least one                                          | 142 (73.6)                   | 147 (38.1)                     | 4.49 (3.09–6.60)  |
| Presence of one                                       | 79 (40.9)                    | 117 (30.3)                     | 3.16 (2.09–4.80)  |
| > one                                                 | 62 (32.6)                    | 28 (7.3)                       | 10.29 (6.04–17.85)|
| Obesity\(^d\)                                         |                              |                                |                   |
| None                                                  | 58 (30.1)                    | 20 (5.2)                       | 7.83 (4.58–13.76) |
| Pregnancy\(^e\)                                       | 23 (28.8)                    | 48 (36.4)                      | 0.71 (0.38–1.29)  |
| Asthma                                                | 14 (7.3)                     | 40 (10.4)                      | 0.68 (0.35–1.26)  |
| Chronic pulmonary disease\(^f\)                        |                              |                                |                   |
| None                                                  | 15 (7.8)                     | 16 (4.1)                       | 1.95 (0.93–4.07)  |
| Presence of one                                       | 35 (18.1)                    | 12 (3.1)                       | 6.88 (3.53–14.09) |
| Autoimmune disease                                    | 25 (13.0)                    | 15 (3.9)                       | 3.67 (1.89–7.30)  |
| Chronic cardiovascular disease\(^g\)                   |                              |                                |                   |
| None                                                  | 29 (15.0)                    | 14 (3.6)                       | 4.68 (2.43–9.34)  |
| Presence of one                                       | 9 (4.7)                      | 5 (1.3)                        | 3.71 (1.23–12.40) |
| Chronic kidney disease                                | 5 (2.6)                      | 1 (0.3)                        | 10.24 (1.4–244.2) |
| Chronic neurological disease/Delay in development\(^i\)| 19 (9.8)                     | 5 (1.3)                        | 8.29 (3.17–25.25) |
| Hemoglobinopathies                                     | 2 (1.0)                      | 4 (1.0)                        | 1.00 (0.13–5.69)  |
| Antiviral treatment                                    |                              |                                |                   |
| No use                                                | 59 (30.6)                    | 87 (22.5)                      | 1                 |
| Yes (use at any moment)                               | 133 (68.9)                   | 295 (76.4)                     | 0.67 (0.45–0.98)  |
| ≤ 48 hours after the onset of symptoms                | 18 (9.3)                     | 137 (35.5)                     | 0.19 (0.11–0.35)  |
| > 48 and ≤ 72 hours after the onset of symptoms       | 10 (5.2)                     | 42 (10.9)                      | 0.35 (0.16–0.74)  |
| > 72 hours after the onset of symptoms                | 105 (54.4)                   | 116 (30.1)                     | 1.33 (0.87–2.04)  |

| Time/Days, median (IQR)\(^c\)                         | CASE                          | CONTROL                        | p-value          |
|------------------------------------------------------|-------------------------------|--------------------------------|------------------|
| First symptoms until hospitalization                  | 5 (3–6)                       | 2 (1–5)                        | < 0.001          |
| Hospitalization until discharge/death                 | 7 (2–15)                      | 4 (2–7)                        | < 0.001          |
| Onset of symptoms until the beginning use of antiviral treatment | 6 (4–8) | 3 (2–5) | < 0.001 |
| Hospitalization until the beginning of antiviral treatment | 1 (0–2) | 0 (0–1) | < 0.001 |

\(^a\) Data collected from hospital records;  
\(^b\) Unadjusted OR  
\(^c\) IQR: Inter-quartile range. Minimum and maximal ages were 0.13 and 84.7 years of age for cases and 0.04 and 85.8 years of age for controls  
\(^d\) Recorded in medical charts;  
\(^e\) The denominator of proportions are women of reproductive age (10 to 49 years), cases (80) and controls (132)  
\(^f\) Chronic pneumonia, chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis;  
\(^g\) Malignant neoplasm, autoimmune disease, use of immunosuppressant (corticosteroids/others), organ transplants and HIV/AIDS;  
\(^h\) Chronic cardiovascular disease, heart failure, peripheral vascular disease, cardiac arrhythmia, congenital disease, ischemic disease;  
\(^i\) Neurological diseases, delay in development, muscular dystrophy and Down’s syndrome;  
\(^j\) 1 case and 4 controls ignored.

doi:10.1371/journal.pone.0118772.t002

age (10 to 49 years). Among children, presence of immunosuppression, chronic cardiovascular disease and neurological disease/delay in development were also risk factors, as well as diabetes
mellitus among women. Treatment with antiviral administered within 72 hours after the onset of symptoms was a protective factor for women of reproductive age.

Tables 4 and 5 show variables associated with death in the final models of multiple logistic regression, in all patients studied and in sub-group analysis of adults (aged 18 years and over). In patients in general, risk factors for death were: being aged between 18 and 59 years (reference: until 18 years), having one or more risk conditions for the severity of the disease, obesity, immunosuppression and having sought care prior to hospitalization. Although chronic neurological diseases/delay in development and chronic liver disease were highly associated with

Table 3. Laboratory tests of patients hospitalized due to influenza A(H1N1)pdm09 associated with Severe Acute Respiratory Illness, who died (case) or recovered (control), metropolitan regions of São Paulo and Campinas, state of São Paulo, Brazil, 2009.

| LABORATORY TESTSa | N   | CASE Median (IQR)b | N   | CONTROL Median (IQR)b | p-value |
|-------------------|-----|--------------------|-----|------------------------|---------|
| Hemoglobin        | 182 | 12.75 (10.8–12.8)   | 305 | 12.6 (11.3–14)         | 0.262   |
| Hematocrit        | 181 | 38.6 (32.6–42)      | 293 | 37.9 (34–41.7)         | 0.974   |
| Leukocytes        | 182 | 6,350 (4,075–9,812.5)| 301 | 7,550 (5,395–10,500)   | 0.002   |
| Platelets         | 179 | 166,000 (123,000–230,000)| 292 | 228,500 (176,000–303,000)| <0.001 |
| Creatine phosphokinase – CPK | 67  | 350 (111–845)      | 35  | 92 (54–217)            | <0.001  |
| Lactic dehydrogenase – LDH | 60  | 881.5 (483–1,907)  | 53  | 422 (255–551.50)       | <0.001  |
| Glutamic-oxaloacetic transaminase—GOT | 118 | 81 (38–133.5)     | 71  | 31 (22–53)             | <0.001  |
| Glutamic-pyruvic transaminase – GPT | 117 | 43.1 (29.5–74)    | 70  | 27.5 (17–41.5)         | <0.001  |
| Urea              | 175 | 32 (23–49)         | 165 | 25 (15.5–34)           | <0.001  |
| Creatinine        | 175 | 0.89 (0.6–1.3)     | 170 | 0.7 (0.5–0.9)          | 0.001   |

a First hospitalization blood test
b IQR: Inter-quartile range.
doi:10.1371/journal.pone.0118772.t003

Risk Factors for Death from Influenza A(H1N1)pdm09

Table 4. Risk factors for death from influenza A(H1N1)pdm09 associated with Severe Acute Respiratory Illness, metropolitan regions of São Paulo and Campinas, state of São Paulo, Brazil, 2009.

| CHARACTERISTICS | ADJUSTED ORa (95% CI) |
|----------------|-----------------------|
| Age group (years) |                        |
| < 18            | 1                     |
| 18–59           | 2.31 (1.31–4.10)      |
| 60 and more     | 1.44 (0.39–5.39)      |
| Risk conditionsb |                        |
| None            | 1                     |
| Presence of one | 1.99 (1.11–3.57)      |
| > one           | 6.05 (2.76–13.28)     |
| Obesityc        | 2.73 (1.28–5.83)      |
| Immunosuppressionc | 3.43 (1.28–9.19)  |
| Previous carec  | 3.35 (1.75–6.40)      |
| Antiviral treatment |                  |
| No use          | 1                     |
| ≤ 48 hours after the onset of symptoms | 0.17 (0.08–0.37) |
| > 48 and ≤ 72 hours after the onset of symptoms | 0.30 (0.11–0.81) |
| > 72 hours after the onset of symptoms | 1.10 (0.62–1.95) |

a significant variables in the final multiple logistic regression model. Hosmer-Lemeshow test = 0.069
b risk conditions for severity of the disease
c Reference category (absence).
doi:10.1371/journal.pone.0118772.t004
death, these variables were excluded from the final model because they had estimates with large confidence intervals. Private health insurance and antiviral treatment administered in the first 72 hours after the onset of symptoms were protective factors against death.

Among adults aged 18 years and over, the risk factors for death were having more than one risk factor for severity of the disease, obesity and care prior to hospitalization. The protective factors were: antiviral drug administered in the first 48 hours after the onset of symptoms and being a health professional or health unit worker.

Sensitivity analysis was performed to assess the severity of patients admitted during the study period. The proportion of ICU admissions and use of mechanical ventilation was estimated for epidemiological week of hospitalization, categorized as EW 26 to 28, EW 29 to 31 and EW 32 to 34. The results showed higher proportions of ICU admissions (50.0% x 16.8% x 7.7%) and mechanical ventilation (45.4% x 10.8% x 2.6%) in the three first weeks, among the controls. The cases showed high proportions in all periods analyzed: 89.7% x 84.0% x 76.9% for need of ICU and 89.7% x 97.6% x 89.7% for need of mechanical ventilation, in the 3 periods, respectively. The opportunity for antiviral treatment showed lower proportion of treatment in the first period of the study, in both cases (37.9% x 74.4% x 74.3%) and controls (59.1% x 74.1% x 89.7%). Sensitivity analysis to assess the opportunity for treatment of children and adults showed similar proportions for the groups: 73.9% and 74%, respectively.

### Discussion

In the present study, risk factors for death were analyzed in patients infected with influenza A (H1N1)pdm09 and hospitalized with SARI. There was an increased risk of death in patients aged 18 to 59 years; those with obesity, immunosuppression, neurological and developmental diseases; or those who had received care prior to hospitalization. Additionally, presence of at least one risk factor for aggravation of the disease was also associated with occurrence of death.
Use of antiviral drugs, especially when administered in the first 72 hours after onset of symptoms was protective factor against death.

The design of this case-control study, including all deaths reported and confirmed in the region during the study period and the time-paired random selection of controls among patients who survived after hospitalization with SARI, with hospital and household data collection, enabled the analysis of the factors associated with death to be extended, including socioeconomic variables, access to health services, and data on hospitalizations.

Few studies have assessed risk factors for death in patients with SARI [15,19]. Some studies have analyzed risk factors for severity of the disease and deaths, comparing patients hospitalized in ICUs and in wards [13,14,20–23], whereas one study used the rate of mortality from influenza A(H1N1)pdm09 in two epidemic waves [24]. A study conducted in Australia analyzed risk factors for hospitalization due to influenza, comparing cases with controls without infection in the community [25]. Other studies have analyzed epidemiological surveillance data, including mortality rates and comparisons among deaths, hospitalizations, treatment and other factors [9,10,12,26–35]. Some of the factors associated with death identified in this study have been described by other authors, such as the presence of comorbidities [31,35], age ≥ 18 years [13], obesity [15,19,20], neurological and developmental diseases [23,24,31] and immunosuppression [15,21,24,34]. Children showed lower risk of death, despite a similar proportion of treatment than adults. A similar result was observed in a study of systematic review and meta-analysis, where the risk of death was 0.28 (95% CI 0.19–0.141), when compared to young adults [36]. In contrast, other factors associated with severity of infection that have been reported by different researchers, such as diabetes [19,34]; other chronic pulmonary diseases, excluding asthma and chronic obstructive pulmonary disease [20]; chronic pulmonary disease, including asthma [31]; and chronic cardiovascular disease [21,24,34], were not associated with mortality in the present study. The population assessed, which was restricted to hospitalized patients with severe influenza could at least partly explain these differences. Diabetes, chronic cardiovascular and kidney disease, associated with death in univariate analysis, did not remain risk factors after multiple analysis. The design of this study, with data collected on medical charts and household interviews, allowed for adjustments in the analysis that can also explain part of these differences.

Deaths occurred mainly in adults aged 18 to 59 years, with a small proportion of cases and controls among elderly individuals. A possible preexisting immunity against the new influenza A(H1N1)pdm09 virus in this age group has been suggested, probably due to previous exposure, through other infections or vaccinations, to an influenza A(H1N1) virus which is genetically and antigenically more associated with the new virus than contemporary strains of seasonal H1N1 viruses [37].

All patients in the present study, whether cases or controls, had a laboratory-confirmed infection of influenza A/H1N1pdm09, which was not similar to the viruses present in the 2009 trivalent influenza vaccine in the Southern hemisphere [A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007 (H3N2) and B/Florida/4/2006] [38].

It is possible that the probability of being hospitalized varied throughout the study. Treatment was available for hospitalized patients and for ambulatory patients with risk conditions for severity. This could have influenced hospitalization, but not much in our study population, consisting of patients with SARI. During the pandemic, criteria for hospitalization changed as well as the availability of treatment, especially in the first 3 weeks of the epidemic, as shown in sensitivity analysis, confirming the need for controlling period of hospitalization in the study.

The socioeconomic profile was similar in both groups assessed, with no difference in income or having private health insurance. There was greater protection against death among patients with an occupation with higher risk of exposure to infection, such as health professionals. A
greater opportunity of access to treatment among these workers could explain such findings, as
the period between the date of onset of symptoms and the date of admission was shorter in this
group. The low proportion of deaths among patients categorized as having a higher risk of ex-
posure has also been observed in other studies [30,33].

Pregnancy was not a risk factor for death in this study. In contrast, frequency of pregnant
women among those of reproductive age hospitalized with severe manifestation of influenza A
(H1N1)pdm09 was high, suggesting that pregnancy could be associated with development of
SARI. An association between pregnancy and use of mechanical ventilation during hospitaliza-
tion due to influenza A(H1N1)pdm2009 [25] and a higher admission rate were reported when
compared to the general population [32]. In 2009, in the state of São Paulo, 27.4% of all con-
firmed cases of influenza A(H1N1)pdm09 in women of reproductive age (10 to 49 years), hos-
Pregnancy was not a risk factor for death in this study. In contrast, frequency of pregnant
women among those of reproductive age hospitalized with severe manifestation of influenza A
(H1N1)pdm09 was high, suggesting that pregnancy could be associated with development of
SARI. An association between pregnancy and use of mechanical ventilation during hospitaliza-
tion due to influenza A(H1N1)pdm2009 [25] and a higher admission rate were reported when
compared to the general population [32]. In 2009, in the state of São Paulo, 27.4% of all con-
firmed cases of influenza A(H1N1)pdm09 in women of reproductive age (10 to 49 years), hos-
Pregnancy was not a risk factor for death in this study. In contrast, frequency of pregnant
women among those of reproductive age hospitalized with severe manifestation of influenza A
(H1N1)pdm09 was high, suggesting that pregnancy could be associated with development of
SARI. An association between pregnancy and use of mechanical ventilation during hospitaliza-
tion due to influenza A(H1N1)pdm2009 [25] and a higher admission rate were reported when
compared to the general population [32]. In 2009, in the state of São Paulo, 27.4% of all con-
firmed cases of influenza A(H1N1)pdm09 in women of reproductive age (10 to 49 years), hos-
Pregnancy was not a risk factor for death in this study. In contrast, frequency of pregnant
women among those of reproductive age hospitalized with severe manifestation of influenza A
(H1N1)pdm09 was high, suggesting that pregnancy could be associated with development of
SARI. An association between pregnancy and use of mechanical ventilation during hospitaliza-
tion due to influenza A(H1N1)pdm2009 [25] and a higher admission rate were reported when
compared to the general population [32]. In 2009, in the state of São Paulo, 27.4% of all con-
firmed cases of influenza A(H1N1)pdm09 in women of reproductive age (10 to 49 years), hos-
difficulties encountered during data collection were minimized by the use of a standardized questionnaire.

In conclusion, the risk conditions for the severity of the disease, particularly obesity, immunosuppression and neurological/developmental diseases, were also important risk factors for death, emphasizing the need for good vaccination coverage during influenza vaccination campaigns in all patients with chronic diseases belonging to more vulnerable groups. Another relevant result was the antiviral treatment within the first 72 hours of onset of symptoms as a protective factor, also emphasizing the need to warn the population about the importance of seeking early medical care when an influenza-like illness appears, especially among high-risk groups and those with signs of disease aggravation. Training of health professionals, especially physicians, is required for adequate clinical management of patients and early antiviral treatment.

Acknowledgments

We would like to thank the Department of Health of the State of São Paulo and the Santa Casa de São Paulo Medical School for their collaboration in the preparation of this project. This study would not have been possible without the collaboration of the researchers and field coordinators, the Epidemiological Surveillance groups of Campinas, Santo André, Franco da Rocha, Osasco and Mogi das Cruzes, the Disease Control Coordination, the Adolfo Lutz Institute, municipal health departments for data collection. We would also like to thank all those who contributed to this study, especially Luiz Roberto Barradas Barata (in memoriam).

Author Contributions

Conceived and designed the experiments: AFR BYK ACGP GM RKMA. Performed the experiments: AFR BYK ACGP GM GCNF RKMA TRMPC DM JF. Analyzed the data: AFR ACGP GM DMTZ. Contributed reagents/materials/analysis tools: AFR ACGP GM DMTZ. Wrote the paper: AFR DMTZ. Reviewed the manuscript: AFR ACGP BYK DM GM GCNF JF RKMA TRMPC DMTZ.

References

1. Subsecretaría de Prevención e Promoción de la Salud. Mexico Ministry of Health. Available: http://www.spps.gob.mx/avisos/89-ah1n1-lecciones-aprendidas.html. Accessed 10 May 2011
2. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children – Southern California, March-April, 2009. MMWR Morb Mortal Wkly Rep. 2009; 58: 400–2. PMID: 19990508
3. Centers for Disease Control and Prevention. Outbreak of swine-origin influenza A (H1N1) virus infections – Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58: 467–70. PMID: 19444150
4. WHO—World Health Organization, Pandemic (H1N1) 2009- Swine flu illness in the United States and Mexico—update 2. Available: http://www.who.int/csr/don/2009_04_26/en/index.html. Accessed 20 May 2010.
5. WHO – World Health Organization, Pandemic (H1N1) 2009- World now at the start of 2009 influenza pandemic. Available: http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html. Accessed 20 May 2010.
6. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Eletrônico Epidemiológico. Caderno Especial Influenza. Influenza pandêmica (H1N1) 2009 – Análise da situação epidemiológica e da resposta ao ano de 2009. Ano 10, n° 2 Março 2010. Available: http://portal.saude.gov.br/portal/arquivos/pdf/boletim_eletronico_influenza_25_03.pdf. Accessed 25 May 2010.
7. São Paulo. Secretaria de Estado da Saúde de São Paulo. Centro de Vigilância Epidemiológica. Influenza A/H1N1 – Casos e óbitos. Available: http://www.cve.saude.sp.gov.br/htm/resp_cobse.htm. Accessed 26 May 2012.
8. São Paulo. Secretaria de Estado da Saúde de São Paulo, Coordenadoria de Controle de Doenças. Informe Técnico: Atualização Influenza A/H1N1 Boletim Epidemiológico Paulista – BEPA. 2009; 6
(69):19–28. Available: http://www.cve.saufe.sp.gov.br/agencia/bepa69_influa.htm. Accessed 12 June 2011.

9. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N Engl J Med. 2009; 360: 2605–15. doi: 10.1056/NEJMoa0903810 PMID: 19423869

10. Chowell G, Bertozzi SM, Colchero AM, Lopez-Gatell H, Aranda CA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009; 361: 674–9. doi: 10.1056/NEJMoa0904023 PMID: 19564633

11. World Health Organization. Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec. 2009; 84: 481–4. PMID: 19928298

12. Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011; 52(S1): S13–S26.

13. Skarbinski J, Jain S, Bramley A, Lee EJ, Huang J, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States—September-October 2009. Clin Infect Dis. 2011; 52 (S1): S50–S59.

14. Godoy P, Rodés A, Álvarez J, Camps N, Barrabeig I, et al. Características de los casos graves hospitalizados por gripe pandémica (H1N1) 2009 en Cataluña. Rev Esp Salud Pública. 2011; 85: 81–7.

15. Santa-Olalla Peralta P, Cortes-García M, Sánchez AL, Prado JA, Pachon del Amo I, et al. Casos de infección por gripe pandémica (H1N1) 2009 hospitalizados en cuidados intensivos en España. Factores asociados a riesgo de muerte, abril 2009–enero 2010. Rev Esp Salud Pública. 2010; 84: 547–67

16. Fukasawa LO, Silva DB, Santos FCP, Oba IT, Araujo AC, et al. Implantação e otimização da PCR em tempo real para o diagnóstico de influenza A(H1N1) no Instituto Adolfo Lutz e perspectiva para 2010. Rev Inst Adolfo Lutz. 2010; 69(1): 131–5.

17. Occupational Safety and Health Act. Guidance on Preparing Workplaces for an Influenza Pandemic. OSHA 3327-05R. Available: http://www.osha.gov/Publications/OSHA3327pandemic.pdf. Accessed 15 May 2011

18. Centers for Disease Control and Prevention – People at High Risk of Developing Flu-Related Complications. Available: http://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed: 20 May 2011.

19. Yokota RTC, Skalinski LM, Igsani CN, de Souza LRO de, Iser BPM, et al. Risk factors for death from influenza A(H1N1)pdm09 in Brazil. Emerg Infect Dis. 2011; 17: 1467–1471. doi: 10.3201/ eid1708.101233 PMID: 21801625

20. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, et al. Risk factors for hospitalization and poor outcome with pandemic A/H1N12009 influenza: United Kingdom first wave (May–September 2009). Thorax. 2010; 65: 645–51. doi: 10.1136/thx.2010.135210 PMID: 20627925

21. Fuhrman C, Bonmarin I, Paty AC, Duport N, Chiron E, et al. Severe Hospitalized 2009 Pandemic Influenza A(H1N1) Cases in France, 1 July–15 November 2009. Euro Surveill. 2010; 15(2): 17–20.

22. Gonzalez-Vélez AE, Díaz-Agero Pérez C, Robustello-Rodela A, Cornejo-Gutierrez AM, Pita-López MJ, et al. Factores asociados a ingreso en unidad de cuidados intensivos en pacientes hospitalizados por influenza pandémica A(H1N1) 2009. Medicina Intensiva. 2011; 35(8): 463–70. doi: 10.1016/j.medin.2011.03.007 PMID: 21536346

23. Jain S, Kamimoto L, Bramley AM, Schimitz AM, Benoit SR, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009; 361: 1935–44. doi: 10.1056/NEJMoa0906695 PMID: 19815859

24. Mytton OT, Rutter PD, Mak M, Stanton EAI, Sachedina N e Donaldson LJ. Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. Epidemiol Infect. 2012; 140: 1533–41. doi: 10.1017/S0950268811001968 PMID: 22044522

25. Ward KA, Spokes PJ, McNulty J.M. Case-control study of risk factors for hospitalization caused by pandemic (H1N1) 2009. Emerg Infect Dis. 2011; 17: 1409–16. doi: 10.3201/eid1708.100842 PMID: 21801617

26. Pérez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009; 361:680–9. doi: 10.1056/NEJMoa0904252 PMID: 19564631

27. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009; 302: 1880–7. doi: 10.1001/jama.2009.1536 PMID: 19822626

28. Louie J, Acosta M, Winter K, Jean C, Gavali S, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009; 302(17): 1896–1902. doi: 10.1001/jama.2009.1583 PMID: 19887665
29. Chowell G, Viboud C, Simonsen L, Miller MA, Eschevarría-Zuno S, et al. Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico. BMC Infect Dis. 2012; 12: 1–11. doi: 10.1186/1471-2334-12-1 PMID: 22214291

30. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA. 2009; 302(17): 1872–79. doi: 10.1001/jama.2009.1496 PMID: 19822627

31. Libster R, Bugna J, Coviello S, Hijaño DR, Dunaiwsky M, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med. 2010; 362: 45–55. doi: 10.1056/NEJMoia0907673 PMID: 20032320

32. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009; 374: 451–8. doi: 10.1016/S0140-6736(09)61304-0 PMID: 19643469

33. Fowlkes AL, Arguin P, Biggerstaff MS, Gindler J, Blau D, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April–July 2009. Clin Infect Dis. 2011; 52(S1): S60–S68.

34. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York City. Clin Infect Dis. 2010; 50(11): 1498–1504. doi: 10.1086/652446 PMID: 20420514

35. Oliveira WK, Carmo EH, Penna GO, Kuchenbecker RS, Santos HB, Araújo WN, et al. Pandemic H1N1 influenza in Brazil: analysis of the first 34 506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill. 2009; 14(22):pii = 19362. PMID: 19883551

36. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk of severe or complicated influenza illness: Systematic review and meta-analysis. BMJ. 2013; 347:1–15.

37. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009; 58(19): 521–4. PMID: 19478718

38. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season. Wkly Epidemiol Record. 2008; 83: 365–372. PMID: 18846715

39. Brasil. Ministério do Planejamento, Orçamento e Gestão. Instituto Brasileiro de Geografia e Estatística, Censo Demográfico 2010. Nupcialidade, fecundidade e migração Resultado da Amostra. Available: http://www.ibge.gov.br/Censos/Censo_Demografico_2010/Nupcialidade_Fecundidade_Migracao/tab1_2.pdf. Accessed 3 February 2013.